临床试验/NCT01058369

NCT01058369终止2 期

Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -

University of Erlangen-Nürnberg Medical School1 个研究点分布在 1 个国家目标入组 2 人开始时间: 2010年4月最近更新: 2020年10月6日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方
入组人数: 2
试验地点: 1
主要终点: Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria (Reduction of Transfusions and/or Increase in Hb, Improvement of Neutropenia and Thrombocytopenia)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Study outline: Deferasirox (Exjade®) is regularly used in severe iron overload in order to avoid organ damage of liver, heart and other organs. It has been proposed, that iron overload may not only impose damage to other organs but also to the bone marrow and thus worsen hematopoietic insufficiency in patients with MDS. Patients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk)
•RAEB I allowed, if clinically stable for > 3 months
•5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of inclusion
•IPSS score < intermediate-1
•transfusion dependent or Hb < 10,5 g/dl
•History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs), except for transfusions for acute bleeding
•Serum ferritin > 300 µg/l and < 1500 μg/l. This level should have been verified at least at two occasions within 3 months. Samples must be obtained in the absence of concomitant severe infection
•no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in the past
•no indication and/or no plans for cytostatic drugs
•no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for G-CSF).
•no indication and/or no plans for stem cell transplantation
•stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening period to >= 8 weeks
•Patients of either gender and age > 18 years
•Life expectancy > 12 months
•Females of childbearing potential must use double-barrier contraception (for example orale contraception and condom).
•Mental ability of the patient to understand explications concerning the study and to understand and follow instructions of the investigating physician
•Written informed consent by the patient

排除标准

•Treatment with deferasirox or other chelation therapy for periods > 4 weeks before study start
•Patients with intolerance to Deferasirox
•Patients with a concomitant second malignant disease, possibly interfering with life expectancy
•Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN
•Patients with uncontrolled systemic hypertension
•Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine clearance < 60 ml/min according to the MDRD formula (Levey 2005)
•History of nephrotic syndrome
•Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
•Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment
•Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days
•Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
•history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;
•history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
•history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase;
•history of urinary obstruction or difficulty in voiding
•History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
•History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by laboratory assays conducted during the screening period
•Patients with active uncontrolled infectious disease
•Pregnancy or breast feeding
•QT > 470 msec on screening ECG
•Patients with a history of Torsades de Pointes

研究组 & 干预措施

Deferasirox

Experimental

干预措施: Deferasirox (Novartis Pharma) (Drug)

结局指标

主要结局

Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria (Reduction of Transfusions and/or Increase in Hb, Improvement of Neutropenia and Thrombocytopenia)

时间窗: within two years

次要结局

Evaluate the Safety and Tolerability Profile of Deferasirox in MDS Patients(within two years)
Development of Bone Marrow Morphology(two years)
Effectiveness of Iron Depletion(within two years)
Overall Survival(within two years)
Correlation Between Hematological Improvement and Effectiveness of Iron Depletion(two years)
Correlation Between Hematological Improvement and Pretreatment Parameters. Extension of This Analysis to MDS Patients on Deferasirox Within the Licensed Indication (More Severe Iron Overload)(two years)
AML-free Survival(within two years)

研究者

发起方

University of Erlangen-Nürnberg Medical School

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

不适用

Early treatment with deferasirox (Exjade®) in low risk MDS - Exjade-Early-TrialPatients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment.

EUCTR2008-006268-12-DEFriedrich-Alexander-Universitaet Erlangen-Nuernberg

终止

2 期

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSMyelodysplastic Syndromes

NCT03920657Fondazione Italiana Sindromi Mielodisplastiche-ETS11

已完成

4 期

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadMyelodysplastic SyndromesTransfusion Dependent Iron Overload

NCT00481143Novartis Pharmaceuticals63

终止

2 期

NCT01159067City of Hope Medical Center1

已完成

不适用

Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox TherapyIron Overload

NCT01874405University of Campania "Luigi Vanvitelli"80